WSG-ADAPT: Trastuzumab Emtansine ± ET vs Trastuzumab + ET in HER2+/HR+ Early Breast Cancer

Slideset - Twelve weeks of trastuzumab emtansine therapy increased the rate of pCR in women with HER2+/HR+ early breast cancer compared with trastuzumab plus endocrine therapy.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research